{"created":"2023-07-27T06:28:34.383132+00:00","id":13167,"links":{},"metadata":{"_buckets":{"deposit":"eeeb2b5a-cec3-472f-9382-b8b090682baf"},"_deposit":{"created_by":3,"id":"13167","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"13167"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00013167","sets":["1132:1133:1134"]},"author_link":["21019","20107","21023","20266","21020","21022","21018","389","21021"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1981-01-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"9","bibliographicPageEnd":"482","bibliographicPageStart":"478","bibliographicVolumeNumber":"305","bibliographic_titles":[{"bibliographic_title":"New England Journal of Medicine"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"We studied the effects of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (KMG-CoA) reductase, on serum levels of lipoproteins and ubiquinone-10 in seven heterozygous patients with familial hypercholesterolemia. ML-236B was given at doses of 30 to 60 mg per day for 24 weeks. Serum cholesterol decreased from 390 ± 9 to 303 ± 8 mg per deciliter (10.1 ± 0.2 to 7.88 ± 0.2 mmol per liter, mean ± S.E.M.; P<0.001), and serum triglyceride decreased from 137 ± 18 to 87 ± 9 mg per deciliter (1.55 ± 0.20 to 0.98 ± 0.1 mmol per liter; P<0.05). Intermediate-density-lipoprotein (IDL) cholesterol, IDL triglyceride, low-density-lipoprotein (LDL) cholesterol, and LDL triglyceride decreased significantly (P<0.01, P<0.02, P<0.001, and P<0.001, respectively). However, there were no significant changes in very-low-density-lipoprotein (VLDL) cholesterol and triglyceride or high-density-lipoprotein (HDL) cholesterol. Serum ubiquinone-10 levels did not change, and LDL levels of ubiquinone-10 decreased by 50 per cent, from 0.39 ± 0.07 to 0.20 ± 0.01 μg per milliliter (P<0.05). No adverse effects were observed. We conclude that ML-236B is effective in lowering serum cholesterol without lowering serum ubiquinone-10 in heterozygous patients with familial hypercholesterolemia.","subitem_description_type":"Abstract"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Massachusetts Medical Society"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1056/nejm198108273050902","subitem_relation_type_select":"DOI"}}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AA00755156","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0028-4793","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Mabuchi, Hiroshi"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Haba, Toshihiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tatami, Ryozo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miyamoto, Susumu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sakai, Yasuyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Wakasugi, Takanobu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Watanabe, Akira"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Koizumi, Junji"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Takeda, Ryoyu"}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-03"}],"displaytype":"detail","filename":"ME-PR-MABUCHI-H-478.pdf","filesize":[{"value":"564.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ME-PR-MABUCHI-H-478.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/13167/files/ME-PR-MABUCHI-H-478.pdf"},"version_id":"84a2af72-5dda-4e96-a74b-932667c57f26"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia"}]},"item_type_id":"4","owner":"3","path":["1134"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-03"},"publish_date":"2017-10-03","publish_status":"0","recid":"13167","relation_version_is_last":true,"title":["Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-07-27T12:28:07.762678+00:00"}